Published in Cancer Res on August 01, 2004
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol (2007) 1.13
Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res (2008) 1.09
Saccharomyces cerevisiae: a versatile eukaryotic system in virology. Microb Cell Fact (2007) 0.93
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91
Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol (2008) 0.91
Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR. Pharmgenomics Pers Med (2015) 0.88
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist (2014) 0.87
Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit. PLoS One (2012) 0.83
Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. MBio (2015) 0.81
IL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses. J Immunother (2012) 0.80
Exploiting fungal cell wall components in vaccines. Semin Immunopathol (2014) 0.80
Kirsten Ras* oncogene: significance of its discovery in human cancer research. Oncotarget (2016) 0.80
Inducing efficient cross-priming using antigen-coated yeast particles. J Immunother (2008) 0.79
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine (2010) 0.78
Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. PLoS One (2014) 0.77
Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo. Vaccine (2015) 0.77
Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol (2005) 2.39
A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood (2007) 1.66
Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst (2006) 1.55
Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther (2003) 1.46
Clara cell: progenitor for the bronchiolar epithelium. Int J Biochem Cell Biol (2009) 1.46
Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J Leukoc Biol (2010) 1.35
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog (2004) 1.32
Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res (2002) 1.31
Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst (2005) 1.21
Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine (2006) 1.16
Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol (2010) 1.16
Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res (2002) 1.16
Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis (2004) 1.16
Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer (2010) 1.13
Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol (2007) 1.13
Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res (2008) 1.09
Negative regulators in homeostasis of naïve peripheral T cells. Immunol Res (2008) 1.05
Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. Am J Physiol Lung Cell Mol Physiol (2004) 1.05
Furin proteolytically processes the heparin-binding region of extracellular superoxide dismutase. J Biol Chem (2002) 1.04
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine (2007) 1.04
Fine mapping and identification of candidate pulmonary adenoma susceptibility 1 genes using advanced intercross lines. Cancer Res (2003) 1.03
Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila) (2009) 1.02
Silibinin modulates TNF-α and IFN-γ mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog (2011) 1.02
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol (2007) 1.01
Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections. Cancer Lett (2003) 1.01
Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res (2010) 1.00
A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res (2008) 0.99
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother (2009) 0.98
Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules. Proc Natl Acad Sci U S A (2002) 0.97
Quantitative analysis of early chemically-induced pulmonary lesions in mice of varying susceptibilities to lung tumorigenesis. Cancer Lett (2005) 0.97
Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther (2005) 0.95
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine (2008) 0.93
Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis. Cancer Immunol Immunother (2014) 0.93
BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. J Thorac Oncol (2006) 0.90
Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis (2003) 0.90
Partial activation precedes apoptotic death in T cells harboring an IAN gene mutation. Eur J Immunol (2004) 0.90
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis (2002) 0.90
Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog (2003) 0.89
BARD1: an independent predictor of survival in non-small cell lung cancer. Int J Cancer (2011) 0.88
TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol (2006) 0.88
Loss of a gimap/ian gene leads to activation of NF-kappaB through a MAPK-dependent pathway. Mol Immunol (2006) 0.88
Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res (2006) 0.88
Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clin Immunol (2004) 0.88
Attenuation of the pulmonary inflammatory response following butylated hydroxytoluene treatment of cytosolic phospholipase A2 null mice. Am J Physiol Lung Cell Mol Physiol (2006) 0.87
Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther (2012) 0.85
Lung tumor growth is stimulated in IFN-gamma-/- mice and inhibited in IL-4Ralpha-/- mice. Anticancer Res (2009) 0.85
Misexpression of MIA disrupts lung morphogenesis and causes neonatal death. Dev Biol (2008) 0.84
Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. J Pharmacol Exp Ther (2004) 0.84
Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol (2002) 0.84
Specific chromosomal aberrations in mouse lung adenocarcinoma cell lines detected by spectral karyotyping: a comparison with human lung adenocarcinoma. Cancer Res (2002) 0.84
Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains. Int J Cancer (2010) 0.84
Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation. Mol Cancer (2011) 0.84
MHC-dependent desensitization of intrinsic anti-self reactivity. Cancer Immunol Immunother (2008) 0.83
Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis (2005) 0.83
Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther (2003) 0.83
Altered expression of splicing factor, heterogeneous nuclear ribonucleoprotein A2/B1, in mouse lung neoplasia. Mol Carcinog (2007) 0.81
The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers. J Thorac Oncol (2010) 0.80
IL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses. J Immunother (2012) 0.80
Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Exp Dermatol (2007) 0.80
Morphological assessment of apoptosis in human lung cells. Methods Mol Med (2003) 0.79
Serum levels of surfactant protein D are increased in mice with lung tumors. Cancer Res (2003) 0.79
Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6-di-tert-butyl-4-methylphenol (BHT) and 2-tert-butyl-4-methyl-6-iso-propylphenol: correlation with quinone methide reactivity. Chem Res Toxicol (2002) 0.79
Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells. Exp Lung Res (2010) 0.78
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine (2010) 0.78
Gap junctional intercellular communication in cells isolated from urethane-induced tumors in A/J mice. DNA Cell Biol (2003) 0.78
Responses of tumorigenic and non-tumorigenic mouse lung epithelial cell lines to electrophilic metabolites of the tumor promoter butylated hydroxytoluene. Chem Biol Interact (2003) 0.77
Animal models of type 1 diabetes: genetics and immunological function. Adv Exp Med Biol (2004) 0.75